The efficacy of silver alloy-coated urinary catheters in preventing urinary tract infection: A meta-analysis

American Journal of Medicine

Volumn 105, Issue 3, 1998, Pages 236-241

  Saint, Sanjay ^a,b   Elmore, Joann G ^a   Sullivan, Sean D ^c   Emerson, Scott S ^a   Koepsell, Thomas D ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALLOY; SILVER; SILVER DERIVATIVE; SILVER OXIDE; UNCLASSIFIED DRUG;

BACTERIURIA; CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; INDWELLING CATHETER; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; PRIORITY JOURNAL; REVIEW; URINARY TRACT INFECTION; URINE CATHETER;

ALLOYS; HUMANS; ODDS RATIO; SILVER; URINARY CATHETERIZATION; URINARY TRACT INFECTIONS;

EID: 0032168034     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9343(98)00240-X     Document Type: Review

References (46)

1. 1. Haley RW, Hooton TM, Culver DH, et al. Nosocomial infections in U.S. hospitals, 1975-1976: estimated frequency by selected characteristics of patients. Am J Med. 1981;70:947-959.
2. 2. Garibaldi RA, Burke JP, Dickman ML, Smith CB. Factors predisposing to bacteriuria during indwelling urethral catheterization. NEJM. 1974;291:215-219.
3. 3. Bryan CS, Reynolds KL. Hospital-acquired bacteremic urinary tract infection: epidemiology and outcome. J Urol. 1984;132:494-498.
4. 4. Krieger JN, Kaiser DL, Wenzel RP. Urinary tract etiology of bloodstream infections in hospitalized patients. J Infect Dis. 1983;148:57-62.
5. 5. Platt R, Polk BF, Murdock B, Rosner B. Mortality associated with nosocomial urinary-tract infection. NEJM. 1982;307:637-642.
6. 6. Platt R, Polk BF, Murdock B, Rosner B. Reduction of mortality associated with nosocomial urinary tract infection. Lancet. 1983;1: 893-897.
7. 7. Green MS, Rubinstein E, Amit P. Estimating the effects of nosocomial infections on the length of hospitalization. J Infect Dis. 1982; 145:667-672.
8. 8. Givens CD, Wenzel RP. Catheter-associated urinary tract infections in surgical patients: a controlled study on the excess morbidity and costs. J Urol. 1980;124:646-648.
9. 9. Gabriel MM, Mayo MS, May LL, et al. In vitro evaluation of the efficacy of a silver-coated catheter. Curr Microbiol. 1996;33:1-5.
10. 10. Liedberg H, Lundeberg T. Silver coating of urinary catheters prevents adherence and growth of Pseudomonas aeruginosa. Urol Res. 1989;17:357-358.
11. 11. McLean RJ, Hussain AA, Sayer M, et al. Antibacterial activity of multilayer silver-copper surface films on catheter material. Can J Microbiol. 1993;39:895-899.
12. 12. Warren JW. The catheter and urinary tract infection. Med Clin North Am. 1991;75:481-493.
13. 13. Stamm WE. Catheter-associated urinary tract infections: epidemiology, pathogenesis, and prevention. Am J Med. 1991;91(3B):65S-71S.
14. 14. Yusuf S. Obtaining medically meaningful answers from an overview of randomized clinical trials. Stat Med. 1987;6:281-294.
15. 15. Light RJ. Accumulating evidence from independent studies: what we can win and what we can lose. Stat Med. 1987;6:221-231.
16. 16. Hennekens CH, Buring JE, Hebert PR. Implications of overviews of randomized trials. Stat Med. 1987;6:397-409.
17. 17. Sacks HS, Berrier J, Reitman D, et al. Meta-analyses of randomized controlled trials. NEJM. 1987;316:450-455.
18. 18. Daifuku R, Stamm WE. Association of rectal and urethral colonization with urinary tract infection in patients with indwelling catheters. JAMA. 1984;252:2028-2030.
19. 19. Gelber RD, Goldhirsch A. Interpretation of results from subset analyses within overviews of randomized clinical trials. Stat Med. 1987;6:371-388.
20. 20. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996;17:1-12.
21. 21. Moher D, Jadad AR, Tugwell P. Assessing the quality of randomized controlled trials. Current issues and future directions. Int J Technol Assess Health Care. 1996;12:195-208.
22. 22. Petitti DB. Meta-analysis, Decision Analysis, and Cost-effectiveness Analysis. New York: Oxford University Press, 1994.
23. 23. Fleiss JL. The statistical basis of meta-analysis. Stat Methods Med Res. 1993;2:121-145.
24. 24. Draper NR, Smith H. Applied Regression Analysis. 2nd ed. New York: Wiley, 1981.
25. 25. Akiyama H, Okamoto S. Prophylaxis of indwelling urethral catheter infection: clinical experience with a modified Foley catheter and drainage system. J Urol. 1979;121:40-42.
26. 26. Nakada J, Kawahara M, Onodera S, Oishi Y. [Clinical study of Silver Lubricath Foley catheter]. Hinyokika Kiyo. 1996;42:433-438.
27. 27. Lundeberg T. Prevention of catheter-associated urinary-tract infections by use of silver-impregnated catheters]. Lancet. 1986;2:1031. Letter.
28. 28. Schaeffer AJ, Story KO, Johnson SM. Effect of silver oxide/trichloroisocyanuric acid antimicrobial urinary drainage system on catheter-associated bacteriuria. J Urol. 1988;139: 69-73.
29. 29. Johnson JR, Roberts PL, Olsen RJ, et al. Prevention of catheter-associated urinary tract infection with a silver oxide-coated urinary catheter: clinical and microbiologic correlates. J Infect Dis. 1990; 162:1145-1150.
30. 30. Liedberg H, Lundeberg T. Silver alloy coated catheters reduce catheter-associated bacteriuria. Br J Urol. 1990;65:379-381.
31. 31. Liedberg H, Lundeberg T, Ekman P. Refinements in the coating of urethral catheters reduces the incidence of catheter-associated bacteriuria. An experimental and clinical study. Eur Urol. 1990;17: 236-240.
32. 32. Liedberg H, Lundeberg T. Prospective study of incidence of urinary tract infection in patients catheterized with bard hydrogel and silver-coated catheters or bard hydrogel-coated catheters. J Urol. 1993;149:405A. Abstract.
33. 33. Takeuchi H, Hida S, Yoshida O, Ueda T. [Clinical study on efficacy of a Foley catheter coated with silver-protein in prevention of urinary tract infections]. Hinyokika Kiyo. 1993;39:293-298.
34. 34. Riley DK, Classen DC, Stevens LE, Burke JP. A large randomized clinical trial of a silver-impregnated urinary catheter: lack of efficacy and staphylococcal superinfection. Am J Med. 1995;98:349-356.
35. 35. Thompson SG. Why sources of heterogeneity in meta-analysis should be investigated. BMJ. 1994;309:1351-1355.
36. 36. Greenland S. Invited commentary: a critical look at some popular meta-analytic methods. Am J Epidemiol. 1994;140:290-296.
37. 37. Greenland S. Quantitative methods in the review of epidemiologic literature. Epidemiol Rev. 1987;9:1-30.
38. 38. Liedberg H. Catheter induced urethral inflammatory reaction and urinary tract infection. An experimental and clinical study. Scand J Urol Nephrol. 1989;124(suppl):1-43.
39. 39. Khan KS, Daya S, Jadad A. The importance of quality of primary studies in producing unbiased systematic reviews. Arch Intern Med. 1996;156:661-666.
40. 40. Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA. 1995;273: 408-412.
41. 41. Kunin CM. Urinary tract infections. Surg Clin North Am. 1980;60: 223-231.
42. 42. Stark RP, Maki DG. Bacteriuria in the catheterized patient. What quantitative level of bacteriuria is relevant? NEJM. 1984;311:560-564.
43. 43. Stamm WE. Urinary tract infections. In: Bennett JV, Brachman PS, eds. Hospitals Infections. 4th ed. Philadelphia: Lippincott-Raven; 1998:481.
44. 44. Fleming TR, DeMets DL. Surrogate end points in clinical trials: are we being misled? Ann Intern Med. 1996;125:605-613.
45. 45. Maki DG. Nosocomial bacteremia. An epidemiologic overview. Am J Med. 1981;70:719-732.
46. 46. Vincent JL, Bihari DJ, Suter PM, et al. The prevalence of nosocomial infection in intensive care units in Europe. Results of the European Prevalence of Infection in Intensive Care (EPIC) Study. EPIC International Advisory Committee. JAMA. 1995;274:639-644.